Thought Leadership

Latest Report

World Preview 2023: Pharma's Age of Uncertainty

The pharmaceutical sector is entering new and unfamiliar territory. Key assumptions, such as the unrivalled profitability of the US market and the reliance on large M&A to spur growth, are getting a serious shake-up.  From the FDA's shifting temperament and the ripple effects of the IRA, commercial disruptions, dealmaking ambiguities and…

Report library

JP Morgan Healthcare Conference 2023

The JP Morgan Healthcare Conference 2023 was the first in-person iteration of the event since 2020. After a rather lacklustre 2022 conference, this year’s event started…

Evaluate Vantage 2023 Preview Infographic

The new year is upon us! What should biopharma companies and investors expect from 2023? Can they hope for better than 2022 or will it be more of the same? We already…

ASH 2022

As the final big conference of the year, ASH is always something a harbinger of things to come. This year was no exception with plenty to keep pharma-watchers pondering…

Evaluate Vantage 2023 Preview

After a tough year for many in biopharma, what’s the outlook for 2023? Evaluate Vantage’s preview sets out the projects waiting in the wings that could drive some…

ASH 2022 Preview

The 2022 ASH Annual Meeting is due to take place on December 10-13 in New Orleans, Louisiana. Get yourself prepared with Evaluate Vantage's preview of the…

Thumbnail

How to spot blockbuster potential?

In 2021, the pharma industry invested over $600 billion in R&D, M&A and licensing in search of the next life-changing and market-leading products. With a patent…

Thumbnail

Q3 Round Up: Alive but not kicking report

What happened in Q3? Did the glimmers of light we saw at the start of the quarter really come to anything or were they a false dawn? In this eBook, we investigate whether…